KA/EN
Register
Medicines reference
Search
Search
Active substance

Fenbendazole

Favourites

Benzimidazole anthelmintic. Registered in Georgia: 7 veterinary products. Forms: chewable tablet, paste, scored tablet, tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Fenbendazole
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
100 mg/kg Dog, Cat Maintenance By mouth once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Panacur small animal 100 mg/ml oral suspension - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Before use

Safety information

Known Drug Interactions

  • Minor warning Fenbendazole + Methimazole
    Thiamazole reduces hepatic oxidation of benzimidazole anthelmintics and can increase their plasma concentrations during concurrent treatment.
    Recommendation: Higher fenbendazole concentrations are expected during concomitant administration.
Latin name
Fenbendazole
Georgian name
ფენბენდაზოლი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
7 of 7 forms
Products
ANTIHELM TRIO, Caniquantel Plus, Caniverm, Caniverm forte, Caniverm mite, Cestal Plus, DADOG
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration7

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

ANTIHELM TRIO, Scored tablet

fenbendazole 200 mg + pyrantel pamoate 144 mg + praziquantel 50 mg, tablet for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Complete manufacturer-labelled canine scope: prevention/treatment of listed nematodes, cestodes and trematodes plus claimed Giardia activity
6.3/10
Situational / acceptable
vetman assessment

ANTIHELM TRIO

fenbendazole 200 mg + pyrantel pamoate 144 mg + praziquantel 50 mg, tablet for dogs and cats
Assessed clinical scopeDog · Complete manufacturer-labelled canine scope: prevention/treatment of listed nematodes, cestodes and trematodes plus claimed Giardia activity · By mouth
Care settingVeterinary risk/diagnosis-led deworming after accurate weighing, with parasite/life-cycle-specific repeat decisions, reinfection control and efficacy testing when failure/resistance is plausible
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 001234 · Verified on 23 Oct 2026

A situational broad-spectrum dog tablet with a credible narrower mixed GI nematode+cestode core, convenient dosing and substantial claim inflation beyond the matching EU evidence. Giardia, trematode, broad larval-stage and blanket prevention claims should not drive use without parasite-specific evidence and regimen.

Regulatory and scientific credibility6.5/10

Exact identity, dog use and dose are supported by current Georgian and Moldovan registrations plus manufacturer instructions; identical-strength EU dog products provide a strong narrower regulatory control. No exact international regulator SPC or public modern assessment supports the much broader Giardia/trematode/prevention claims.

Clinical efficacy5.0/10

Praziquantel/pyrantel/fenbendazole at 5/14.4/20 mg/kg has a current identical-strength EU dog authorisation for defined mixed GI nematode+cestode stages, so that narrower core is credible. The manufacturer extends one dose to larval stages, Strongyloides, prevention, several trematodes and Giardia without direct exact-product outcomes; a single 20 mg/kg fenbendazole exposure is not a guideline Giardia course.

Safety and tolerability6.5/10

The manufacturer reports no signs at 3-5x dose and twice-duration exposure in dogs, and the active classes are generally well tolerated. Confidence is limited by no independent exact safety report, broad organ/illness/reproductive exclusions and cholinergic interactions; GI or nonspecific reactions remain possible.

Clinical practicality8.0/10

One dose, no fasting, direct/food administration, quarter scoring and individual sachets are convenient. Accurate weighing and deliverable quarter increments remain necessary above 10 kg; repeat/quarterly prevention requires a parasite-risk plan rather than automatic calendar use.

Full-course cost-effectiveness-

Current Georgian course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this dog score covers the complete manufacturer-labelled nematode, cestode, trematode, prevention and claimed Giardia scope. Evidence is materially stronger for a narrower GI nematode+cestode core; presence of an active does not validate every listed organism/stage.
  • Diagnose/risk-assess before dosing: use faecal testing, visible segments, exposure and local epidemiology as appropriate. Echinococcus requires public-health procedures; severe hookworm disease may need stabilization and suspected treatment failure needs quantitative follow-up.
  • Exact dose: accurately weigh; give 1/4 tablet at 1-2.5 kg, 1/2 at >2.5-5 kg, 1 at >5-10 kg, then 0.1 tablet/kg in deliverable quarter increments. Give once directly or with food; no fasting/laxative. Do not round an undeliverable result.
  • Giardia boundary: one tablet/10 kg supplies fenbendazole 20 mg/kg once. This is not the multi-day fenbendazole-containing regimen described by current giardiosis guidance; do not diagnose/treat Giardia from the ingredient list or repeat empirically without diagnostic and hygiene control.
  • Broad-claim boundary: identical-strength EU dog products restrict use to defined mixed GI nematode+cestode stages and when both groups need treatment. Strongyloides, trematodes, broad larval stages and blanket prevention in this manufacturer label lack an equivalent exact-product public outcome dossier.
  • Repeat/prevention: repeat after 10-14 days only when parasite biology, diagnosis or risk indicates. Routine quarterly use is not universally optimal; tailor lifetime control to age, geography, hunting/raw diet, travel, household and faecal surveillance, limiting unnecessary selection pressure.
  • Reinfection/resistance: control fleas for Dipylidium, prey/raw offal for Taenia/Echinococcus and faecal/environment contamination. Persistent eggs/signs require adherence, reinfection, species/stage and resistance assessment—not automatic use of the same combination.
  • Do not use below 4 weeks in dogs or 6 weeks in cats, from one week before through two weeks after parturition, or in infectious disease, exhaustion/debilitation, renal/hepatic impairment or hypersensitivity. Lactation is allowed only once offspring exceed those age limits.
  • Do not combine with piperazine derivatives, levamisole, organophosphates or other cholinergic medicines. Stop/reassess clinically significant vomiting, diarrhoea, anorexia, lethargy, depression or neurologic/cholinergic signs; no specific overdose antidote is stated.
  • Dog overdose/handling boundary: manufacturer tolerance at 3-5x in dogs is not permission to round or stack products. Confirm full ingestion, keep each sachet from children/animals, wash hands and review all concurrent parasite preventives to avoid duplicate actives.
Assessment sources
  1. ANTIHELM TRIO GE register2026
  2. Vetsintez instruction2026
  3. ANTIHELM TRIO Moldova2026
  4. DV8WORM exact-strength control2026
  5. Caniverm species control2026
  6. ESCCAP worm control 20252025
  7. ESCCAP Giardia control2025
  8. CAPC hookworms 20252025
  9. FDA pyrantel praziquantel control2007
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Complete manufacturer-labelled feline scope: prevention/treatment of listed nematodes, cestodes and trematodes plus claimed Giardia activity
5.3/10
Weak evidence support
vetman assessment

ANTIHELM TRIO

fenbendazole 200 mg + pyrantel pamoate 144 mg + praziquantel 50 mg, tablet for dogs and cats
Assessed clinical scopeCat · Complete manufacturer-labelled feline scope: prevention/treatment of listed nematodes, cestodes and trematodes plus claimed Giardia activity · By mouth
Care settingVeterinary risk/diagnosis-led deworming after accurate weighing, with parasite/life-cycle-specific repeat decisions, reinfection control and efficacy testing when failure/resistance is plausible
vetman score 5.3/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 001234 · Verified on 23 Oct 2026

A weak feline option despite local authorisation: key active classes are plausible, but the exact one-dose broad cat scope lacks an international exact-product evidence bridge and the manufacturer flags greater feline overdose sensitivity. Prefer parasite-specific, regulator-supported feline regimens when available.

Regulatory and scientific credibility6.0/10

Exact local cat registration and manufacturer directions are corroborated by Moldova; authorised EU cat/dog three-active products exist but differ in fenbendazole strength/presentation. No exact internationally regulated feline bridge or public assessment supports the full extended scope.

Clinical efficacy3.5/10

Praziquantel and pyrantel support important feline cestode/nematode endpoints, and other regulated cat/dog triple products support class plausibility. However, no exact-composition feline outcome/authorisation bridge validates the one-dose broad larval, Strongyloides, trematode, prevention or Giardia scope; weight bands also create variable exposure in small cats.

Safety and tolerability5.5/10

The manufacturer explicitly states cats are more overdose-sensitive and may develop depression, vomiting or diarrhoea, without a specific antidote. Quarter-band exposure rises at the low end, and age, periparturient, organ-disease, illness/debilitation and cholinergic-interaction exclusions materially narrow safe use.

Clinical practicality7.0/10

One dose, no fasting, food administration and quarter scoring help, including 1-2.5 kg cats. Small-bodyweight bands create relatively large exposure steps, exact quartering/ingestion must be confirmed and feline overdose sensitivity makes rounding or unsupervised repeating unacceptable.

Full-course cost-effectiveness-

Current Georgian course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this cat score covers the complete manufacturer-labelled nematode, cestode, trematode, prevention and claimed Giardia scope. Evidence is materially stronger for a narrower GI nematode+cestode core; presence of an active does not validate every listed organism/stage.
  • Diagnose/risk-assess before dosing: use faecal testing, visible segments, exposure and local epidemiology as appropriate. Echinococcus requires public-health procedures; severe hookworm disease may need stabilization and suspected treatment failure needs quantitative follow-up.
  • Exact dose: accurately weigh; give 1/4 tablet at 1-2.5 kg, 1/2 at >2.5-5 kg, 1 at >5-10 kg, then 0.1 tablet/kg in deliverable quarter increments. Give once directly or with food; no fasting/laxative. Do not round an undeliverable result.
  • Giardia boundary: one tablet/10 kg supplies fenbendazole 20 mg/kg once. This is not the multi-day fenbendazole-containing regimen described by current giardiosis guidance; do not diagnose/treat Giardia from the ingredient list or repeat empirically without diagnostic and hygiene control.
  • Broad-claim boundary: identical-strength EU dog products restrict use to defined mixed GI nematode+cestode stages and when both groups need treatment. Strongyloides, trematodes, broad larval stages and blanket prevention in this manufacturer label lack an equivalent exact-product public outcome dossier.
  • Repeat/prevention: repeat after 10-14 days only when parasite biology, diagnosis or risk indicates. Routine quarterly use is not universally optimal; tailor lifetime control to age, geography, hunting/raw diet, travel, household and faecal surveillance, limiting unnecessary selection pressure.
  • Reinfection/resistance: control fleas for Dipylidium, prey/raw offal for Taenia/Echinococcus and faecal/environment contamination. Persistent eggs/signs require adherence, reinfection, species/stage and resistance assessment—not automatic use of the same combination.
  • Do not use below 4 weeks in dogs or 6 weeks in cats, from one week before through two weeks after parturition, or in infectious disease, exhaustion/debilitation, renal/hepatic impairment or hypersensitivity. Lactation is allowed only once offspring exceed those age limits.
  • Do not combine with piperazine derivatives, levamisole, organophosphates or other cholinergic medicines. Stop/reassess clinically significant vomiting, diarrhoea, anorexia, lethargy, depression or neurologic/cholinergic signs; no specific overdose antidote is stated.
  • Feline overdose warning: the manufacturer states cats are more sensitive; depression, vomiting and diarrhoea may occur. Quarter-tablet bands yield higher mg/kg exposure at the low end, so never round up, redose after vomiting or combine dewormers without a veterinarian-directed calculation.
Assessment sources
  1. ANTIHELM TRIO GE register2026
  2. Vetsintez instruction2026
  3. ANTIHELM TRIO Moldova2026
  4. DV8WORM exact-strength control2026
  5. Caniverm species control2026
  6. ESCCAP worm control 20252025
  7. ESCCAP Giardia control2025
  8. CAPC hookworms 20252025
  9. FDA pyrantel praziquantel control2007
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fenbendazole200 mg Pyrantel144 mg Praziquantel50 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Vetsintez Ltd · Ukraine
Manufacturer (register)
Vetsintez Ltd, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1839, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 05 Aug 2031
Veterinary (National Food Agency)
In the register: ანტიჰელმი ტრიო 0.8 გ
№ 001234
Verified on: 23 Oct 2026
 EU No
Verified on: 23 Oct 2026
 UK No
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Manufacturer-labelled scope includes prevention/treatment of listed nematodes, cestodes and trematodes, with additional Giardia activity claimed in pharmacology text; evidence is substantially stronger for a narrower GI nematode+cestode scope. Give the exact weight-band dose once with food or directly; fasting/laxative is unnecessary. Repeat after 10-14 days only when diagnosis/life cycle/risk indicates. Quarter-tablet steps must be deliverable after accurate weighing.

Caniquantel Plus, Scored tablet

fenbendazole 500 mg + praziquantel 50 mg, flavoured tablet
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in dogs
7.8/10
Good
vetman assessment

Caniquantel Plus

fenbendazole 500 mg + praziquantel 50 mg, flavoured tablet
Assessed clinical scopeDog · Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in dogs · By mouth
Care settingVeterinary-directed outpatient or preventive care
vetman score 7.8/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 203-11 · Verified on 15 Oct 2026

A well-documented and practical broad-spectrum oral wormer for dogs, with good label transparency but limited independent evidence for the exact combination.

Regulatory and scientific credibility7.5/10

The exact composition, species, route and current dose table are documented by two European regulatory sources and the product has active Georgian veterinary registration (203-11); independent formulation-specific outcome evidence is limited.

Clinical efficacy7.5/10

The fenbendazole-praziquantel combination covers common susceptible roundworms and tapeworms, but efficacy depends on correct parasite identification, label schedule and local susceptibility rather than the brand name alone.

Safety and tolerability8.0/10

The reviewed exact label lists no contraindications or known adverse effects and permits use in labelled breeding schedules; correct dosing and individual hypersensitivity precautions still apply.

Clinical practicality8.5/10

A flavoured, crushable, cross-scored tablet with quarter-tablet dog bands and usually single-dose administration is highly workable across a broad weight range.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • The reviewed exact label reports no contraindications or known adverse effects at the recommended dose.
  • Use parasite diagnosis and the product-specific schedule; do not derive the combination dose from either ingredient alone.
Assessment sources
  1. ÚSKVBL leaflet 20242024
  2. EMA UPD 20252025
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in cats
7.7/10
Good
vetman assessment

Caniquantel Plus

fenbendazole 500 mg + praziquantel 50 mg, flavoured tablet
Assessed clinical scopeCat · Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in cats · By mouth
Care settingVeterinary-directed outpatient or preventive care
vetman score 7.7/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 203-11 · Verified on 15 Oct 2026

A practical labelled cat wormer with transparent dosing; the slightly lower safety score reflects the label's explicit feline overdose sensitivity.

Regulatory and scientific credibility7.5/10

The exact composition, feline indication, route and current dose table are documented by two European regulatory sources and the product has active Georgian veterinary registration (203-11); independent exact-formulation evidence is limited.

Clinical efficacy7.5/10

The combination provides useful labelled roundworm and tapeworm coverage in cats, subject to correct parasite diagnosis and the product-specific schedule.

Safety and tolerability7.5/10

The exact label reports no known adverse effects at the recommended dose, but notes transient nausea, vomiting or diarrhoea after overdose and greater feline sensitivity than in dogs.

Clinical practicality8.5/10

Quarter-tablet dosing, crushability and a usually single administration are practical; the fixed three-quarter-tablet band above 4 kg still requires strict adherence to this product label.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Cats are described as more overdose-sensitive than dogs; excess dosing may cause transient nausea, vomiting or diarrhoea.
  • Use the feline weight table exactly; do not calculate this combination from a single ingredient rule.
Assessment sources
  1. ÚSKVBL leaflet 20242024
  2. EMA UPD 20252025
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fenbendazole500 mg Praziquantel50 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Loxavet pharma · Germany
Manufacturer (register)
GmbH. Co.KG Artesan Pharma GmbH. Co.KG, Germany
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 682, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კანიქვანტელი® პლუსი
№ 203-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Caniverm, Paste

oral paste, fenbendazole 75 mg + pyrantel embonate 72 mg + praziquantel 25 mg per ml, oral paste for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats
7.9/10
Good
vetman assessment

Caniverm

oral paste, fenbendazole 75 mg + pyrantel embonate 72 mg + praziquantel 25 mg per ml, oral paste for dogs and cats
Assessed clinical scopeDog · Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats · By mouth
Care settingWeight-based single-dose oral deworming after parasite-risk and label-band assessment
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 18 Oct 2026

A practical, officially documented broad-spectrum oral paste with sound ingredient-level support; confidence is moderated by limited independent exact-product trials.

Regulatory and scientific credibility8.5/10

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Clinical efficacy7.5/10

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

Safety and tolerability7.5/10

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

Clinical practicality8.0/10

The graduated paste supports small-patient dosing and direct oral delivery, but accurate weighing, applicator measurement and complete swallowing remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Complementary feed, not a veterinary medicine. Category-correct “not applicable” medicine-authorisation status does not establish regulator-reviewed efficacy, quantitative enzyme activity or safety.
  • The current manufacturer page names amylase and lipase but publishes no source, amount, activity units, protease, capsule-content mass, complete excipients, batch-potency limits or exact-product study. Do not infer a pancreatic-extract-equivalent dose.
Assessment sources
  1. UPD SPC 20262026
  2. Fenbendazole-praziquantel dog trial2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats
7.9/10
Good
vetman assessment

Caniverm

oral paste, fenbendazole 75 mg + pyrantel embonate 72 mg + praziquantel 25 mg per ml, oral paste for dogs and cats
Assessed clinical scopeCat · Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats · By mouth
Care settingWeight-based single-dose oral deworming after parasite-risk and label-band assessment
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 18 Oct 2026

A practical, officially documented broad-spectrum oral paste with sound ingredient-level support; confidence is moderated by limited independent exact-product trials.

Regulatory and scientific credibility8.5/10

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Clinical efficacy7.5/10

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

Safety and tolerability7.5/10

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

Clinical practicality8.0/10

The graduated paste supports small-patient dosing and direct oral delivery, but accurate weighing, applicator measurement and complete swallowing remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Complementary feed, not a veterinary medicine. Category-correct “not applicable” medicine-authorisation status does not establish regulator-reviewed efficacy, quantitative enzyme activity or safety.
  • The current manufacturer page names amylase and lipase but publishes no source, amount, activity units, protease, capsule-content mass, complete excipients, batch-potency limits or exact-product study. Do not infer a pancreatic-extract-equivalent dose.
Assessment sources
  1. UPD SPC 20262026
  2. Fenbendazole-praziquantel dog trial2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fenbendazole75 mg/ml Pyrantel72 mg/ml Praziquantel25 mg/ml
Formulation Type
Paste
Administration route
By mouth
Manufacturer
Bioveta · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კანივერმი პერორალური პასტა
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ 96/026/12-C
Verified on: 18 Oct 2026
 UK No
Verified on: 18 Oct 2026
 US No
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Caniverm forte, Scored tablet

fenbendazole 150 mg + pyrantel embonate 144 mg + praziquantel 50 mg, tablet
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in dogs weighing at least 2 kg
7.3/10
Good
vetman assessment

Caniverm forte

fenbendazole 150 mg + pyrantel embonate 144 mg + praziquantel 50 mg, tablet
Assessed clinical scopeDog · Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in dogs weighing at least 2 kg · By mouth
Care settingVeterinary-directed outpatient or preventive care
vetman score 7.3/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 194-11, 226-11 · Verified on 18 Oct 2026

A useful broad-spectrum dog wormer with a current exact label, offset by meaningful contraindications and less flexible weight-band dosing.

Regulatory and scientific credibility7.5/10

A current official Czech package leaflet verifies the exact formulation and dose bands, supported by active Georgian veterinary registration (194-11/226-11); independent formulation-specific evidence remains limited.

Clinical efficacy7.5/10

The three-drug combination supplies broad susceptible nematode and cestode coverage, but outcome depends on parasite diagnosis and label-concordant dosing.

Safety and tolerability7.0/10

A wide margin is described after overdose, but liver damage, ocular cysticercosis, spinal neurocysticercosis, hypersensitivity and prohibited antiparasitic combinations require patient selection.

Clinical practicality7.0/10

Usually single-dose, scored oral administration is workable, but the forte tablet has no labelled dog dose below 2 kg and rounds every started 10 kg above 10 kg.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with liver damage, ocular cysticercosis, spinal neurocysticercosis or known hypersensitivity.
  • Do not combine with piperazine-containing or other antiparasitic products.
  • The forte label has no dog dose below 2 kg; use an appropriately labelled lower-strength presentation.
Assessment sources
  1. ÚSKVBL leaflet 20262026
  2. Bioveta guide 20232023
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in cats weighing 2-5 kg
7.2/10
Good
vetman assessment

Caniverm forte

fenbendazole 150 mg + pyrantel embonate 144 mg + praziquantel 50 mg, tablet
Assessed clinical scopeCat · Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in cats weighing 2-5 kg · By mouth
Care settingVeterinary-directed outpatient or preventive care within the labelled weight band
vetman score 7.2/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 194-11, 226-11 · Verified on 18 Oct 2026

A credible but weight-restricted feline option; outside 2-5 kg, another labelled presentation is preferable rather than extrapolating this tablet.

Regulatory and scientific credibility7.5/10

A current official Czech leaflet verifies the exact feline formulation and dose, supported by active Georgian veterinary registration (194-11/226-11); independent exact-formulation evidence is limited.

Clinical efficacy7.5/10

The combination offers broad susceptible intestinal nematode and cestode coverage within its narrow labelled feline weight band.

Safety and tolerability7.0/10

The label reports a wide overdose margin, but the same liver, cysticercosis, hypersensitivity and combination restrictions apply.

Clinical practicality6.5/10

A single half-tablet dose is simple for 2-5 kg cats, but no dose is established on this forte label below 2 kg or above 5 kg, materially narrowing practical use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with liver damage, ocular cysticercosis, spinal neurocysticercosis or known hypersensitivity.
  • Do not combine with piperazine-containing or other antiparasitic products.
  • The forte label establishes a feline dose only from 2 to 5 kg; do not extrapolate outside that band.
Assessment sources
  1. ÚSKVBL leaflet 20262026
  2. Bioveta guide 20232023
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fenbendazole150 mg Pyrantel144 mg Praziquantel50 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Bioveta · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კანივერმი ფორტე ტაბლეტები
№ 194-11, 226-11
Verified on: 18 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Caniverm mite, Scored tablet

fenbendazole 37.5 mg + pyrantel embonate 36 mg + praziquantel 12.5 mg, tablet
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats
7.8/10
Good
vetman assessment

Caniverm mite

fenbendazole 37.5 mg + pyrantel embonate 36 mg + praziquantel 12.5 mg, tablet
Assessed clinical scopeDog · Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats · By mouth
Care settingWeight-based single-dose oral deworming after parasite-risk and label-band assessment
vetman score 7.8/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 197-11, 177-11, 209-11 · Verified on 18 Oct 2026

A useful low-weight broad-spectrum tablet with an exact official label; confidence is moderated by limited independent exact-product trials and narrow weight bands.

Regulatory and scientific credibility8.5/10

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Clinical efficacy7.5/10

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

Safety and tolerability7.5/10

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

Clinical practicality7.5/10

The small scored tablet is useful for puppies, small dogs and cats, but its labelled weight bands are narrow and exact weighing is essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Complementary feed, not a veterinary medicine. Category-correct “not applicable” medicine-authorisation status does not establish regulator-reviewed efficacy, quantitative enzyme activity or safety.
  • The current manufacturer page names amylase and lipase but publishes no source, amount, activity units, protease, capsule-content mass, complete excipients, batch-potency limits or exact-product study. Do not infer a pancreatic-extract-equivalent dose.
Assessment sources
  1. ÚSKVBL leaflet 20262026
  2. Fenbendazole-praziquantel dog trial2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats
7.8/10
Good
vetman assessment

Caniverm mite

fenbendazole 37.5 mg + pyrantel embonate 36 mg + praziquantel 12.5 mg, tablet
Assessed clinical scopeCat · Full labelled treatment scope for susceptible intestinal roundworms and tapeworms in dogs and cats · By mouth
Care settingWeight-based single-dose oral deworming after parasite-risk and label-band assessment
vetman score 7.8/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 197-11, 177-11, 209-11 · Verified on 18 Oct 2026

A useful low-weight broad-spectrum tablet with an exact official label; confidence is moderated by limited independent exact-product trials and narrow weight bands.

Regulatory and scientific credibility8.5/10

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Clinical efficacy7.5/10

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

Safety and tolerability7.5/10

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

Clinical practicality7.5/10

The small scored tablet is useful for puppies, small dogs and cats, but its labelled weight bands are narrow and exact weighing is essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Complementary feed, not a veterinary medicine. Category-correct “not applicable” medicine-authorisation status does not establish regulator-reviewed efficacy, quantitative enzyme activity or safety.
  • The current manufacturer page names amylase and lipase but publishes no source, amount, activity units, protease, capsule-content mass, complete excipients, batch-potency limits or exact-product study. Do not infer a pancreatic-extract-equivalent dose.
Assessment sources
  1. ÚSKVBL leaflet 20262026
  2. Fenbendazole-praziquantel dog trial2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fenbendazole37.5 mg Pyrantel36 mg Praziquantel12.5 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Bioveta · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კანივერმი მიტე ტაბლეტები
№ 197-11, 177-11, 209-11
Verified on: 18 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Cestal Plus, Chewable tablet

praziquantel 50 mg + pyrantel embonate 144 mg + fenbendazole 200 mg, chewable tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.9/10
Good
vetman assessment

Cestal Plus

praziquantel 50 mg + pyrantel embonate 144 mg + fenbendazole 200 mg, chewable tablet for dogs
Assessed clinical scopeDog · Labelled treatment and routine control of susceptible gastrointestinal nematodes and cestodes in dogs · By mouth
Care settingVeterinary-directed outpatient or preventive care
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 299-11 · Verified on 21 Oct 2026

A very practical, transparently labelled broad-spectrum dog wormer; appropriate parasite diagnosis and the product-specific schedule remain essential.

Regulatory and scientific credibility8.0/10

The exact three-drug product, current SPC dose table and authorisation are documented in the EU database, with active Georgian veterinary registration (299-11).

Clinical efficacy8.0/10

The labelled praziquantel-pyrantel-fenbendazole combination provides useful broad coverage of susceptible canine intestinal nematodes and cestodes with a product-specific regimen.

Safety and tolerability7.5/10

The label-defined restrictions are manageable but relevant: do not use below 4 weeks, with piperazine or in hypersensitive animals; routine antiparasitic stewardship remains necessary.

Clinical practicality8.5/10

The palatable chewable tablet can be quartered, given with or without food and is usually administered once across clear weight bands.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use concurrently with piperazine.
  • Do not use in puppies younger than 4 weeks or in animals hypersensitive to the ingredients.
  • Dose this three-drug product by its own label; single-ingredient fenbendazole rules do not apply.
Assessment sources
  1. EMA UPD 20242024
  2. EU UPD Cestal Plus2026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Praziquantel50 mg Pyrantel144 mg Fenbendazole200 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Lavet Pharmaceuticals Ltd · Hungary
Manufacturer (register)
Lavet pharmaceuticals, Hungary
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 221, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ცესტალ პლუსი ფლავორი
№ 299-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

DADOG 50/150/200 mg tablets, Tablet

N48 for dogs and puppies
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.6/10
Weak evidence support
vetman assessment

DADOG

50/150/200 mg tablets, N48 for dogs and puppies
Assessed clinical scopeDog · Full dog label from 3 weeks: single-dose treatment of mixed gastrointestinal nematode and cestode infections with praziquantel, pyrantel and fenbendazole · By mouth
Care settingVeterinary-directed routine or diagnosis-led deworming of a weighed dog, given at home or in the clinic
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 002547 · Verified on 21 Oct 2026

A weak option: a locally made triple combination with a sound praziquantel and pyrantel base, but a low single fenbendazole dose, a gap in the dosing table and a registration about to expire.

Regulatory and scientific credibility4.5/10

The exact product is registered in Georgia (002547) by a Georgian manufacturer with a current distributor instruction, but the registration expires on 2 November 2026, the English text carries a known dosing error and no EU, UK or US authorisation was documented in the reviewed evidence or product study.

Clinical efficacy6.0/10

Praziquantel and pyrantel are well supported at 1 tablet per 10 kg, but fenbendazole is only 20 mg/kg as a single dose, well below EU single-dose fenbendazole combinations, so its added whipworm and roundworm effect is uncertain.

Safety and tolerability6.0/10

Pyrantel and fenbendazole are well tolerated and use is allowed from 3 weeks, but the instruction gives no pregnancy guidance and no independent safety data exist.

Clinical practicality6.0/10

The Georgian label gives practical bands up to 50 kg, but the 20-30 kg band is missing and quarter-tablet doses for dogs under 2 kg are hard to measure.

Full-course cost-effectiveness-

No verified current Georgian price or patient-adjusted course cost was found; foreign prices were not substituted.

Important safety and use flags

  • Georgian registration 002547 is valid only to 2 November 2026; confirm renewal before stocking or prescribing.
  • The label table has no 20-30 kg band; keep to 1 tablet per 10 kg (3 tablets) and ignore the English page's 4-tablet 10-30 kg line.
  • Do not combine with piperazine, morantel or levamisole.
  • The instruction has no pregnancy statement; avoid in pregnant bitches unless a veterinarian judges the benefit greater.
  • A single low fenbendazole dose may not clear Trichuris; recheck faeces if whipworm was diagnosed.
Assessment sources
  1. Davati DADOG instruction2026
  2. Georgia NFA register 20262026
  3. ESCCAP worm control guideline2026
  4. WSAVA essential medicines 20232023
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Praziquantel50 mg/tablet Pyrantel150 mg/tablet Fenbendazole200 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Davati Ltd · Georgia
Manufacturer (register)
Davati Ltd, Georgia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 492, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 02 Nov 2026
Veterinary (National Food Agency)
In the register: დადოგი
№ 002547
Verified on: 21 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗